

Appl. No. 09/933,131
Amdt. Dated February 24, 2004
Reply to Office action of August 26, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of inhibiting tumor lymphoma cell growth or proliferation comprising administering an effective amount of (i) a regulatory T-cell having the phenotype $CD3^+ \alpha\beta-TcR^+ CD4^+ CD8^- CD44^- CD28^- NK1.1^-$, or (ii) ~~an agent that can induce or activate the regulatory T-cell~~ to an animal in need of such treatment.

Claims 2-3 (deleted).

Claim 4 (original): A method according to claim 1 wherein the regulatory T cells are expanded or activated *in vitro* prior to administration by culturing the cells with IL-2 and IL-4.

Claim 5 (original): A method according to claim 4 further comprising culturing the cells with one class I mismatched allogeneic lymphocytes.

Claim 6 (original): A method according to claim 1 wherein the regulatory T cells are expanded or activated *in vitro* prior to administration by culturing the cells in the presence of an antigen.

Claim 7 (currently amended) A method according to claim 1 to treat ~~cancer~~ lymphoma.

Claims 8-11 (deleted).